AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic MigraineGlobeNewsWire • 05/03/24
Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 04/19/24
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of MigraineGlobeNewsWire • 03/19/24
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase AgreementsGlobeNewsWire • 03/19/24
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin ConferenceGlobeNewsWire • 01/18/24
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic MigraineGlobeNewsWire • 12/12/23
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic MigraineGlobeNewsWire • 10/19/23
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®GlobeNewsWire • 08/29/23
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine HeadacheGlobeNewsWire • 08/24/23
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON BiopharmaGlobeNewsWire • 08/16/23
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline UpdateGlobeNewsWire • 07/24/23